New Directors Introduced at LifeSciences BC's Annual General Meeting and Partner Appreciation ReceptionSeptember 23, 2008As our kick-off for National Biotech Week in Canada, LifeSciences BC held our 2008 Annual General Meeting on September 23rd. The meeting highlighted exciting accomplishments from the past year, and outlined LifeSciences BC’s plans for 2008/2009. LifeSciences BC is delighted to welcome our new directors. Mr. Ian Thompson, President, Canadian BioEnergy was appointed as of the September 16th Board of Directors’ meeting, and Dr. Steven Gillis, Managing Director, ARCH Venture Partners; and Mr. Gordon MacCauley, President & Chief Executive Officer, Allon Therapeutics were elected to LifeSciences BC’s Board of Directors at yesterday’s Annual General Meeting. Dr. Robert Sindelar of UBC was also re-elected to the Board of Directors. LifeSciences BC wishes to express our thanks once again to our retiring Directors for their outstanding contributions to our association and the entire industry. Please read our news release for more details about our new directors. The meeting was followed by our second annual Partner Appreciation Reception at the Vancouver Club, where meeting attendees and others enjoyed cocktails and canapes. Thanks to all our members, sponsors and partners for the tremendous support you've shown us! Download the slideshow  LifeSciences BC members listen as Chair Simon Pimstone addresses the gatehring Bios: Steven Gillis Managing Director, ARCH Venture Partners    Steven Gillis, Ph.D. is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. He is a director of Trubion Pharmaceuticals (TRBN), Allozyne, Variation Biotechnologies, Magen BioSciences, Surface Logix, PhaseRx, Accelerator, and Surface Logix. He serves as director and Chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST. Dr. Gillis was a founder and director of Corixa Corp. and served as the company's CEO from its inception and as its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex's Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex's R&D subsidiary. Dr. Gillis was interim CEO of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College. Gordon C. McCauley President & Chief Executive Officer, Allon Therapeutics  Gordon McCauley was appointed President of Allon in 2004. Mr. McCauley is a co-founder, and the former President and COO of Neuro Discovery Inc., now NDI Capital. Prior to co-founding NDI, he led the successful growth and development of two Canadian healthcare companies. Outside of the healthcare industry, Mr. McCauley has been a senior sales and public affairs executive for a Canadian multinational energy company and served in a staff capacity to two Prime Ministers and former Ontario Premier David Peterson. Mr. McCauley serves on the Board of Hallmark Insurance, ACETECH, BIOTECanada, and the Biotechnology Industry Organization (BIO), Washington, D.C. Ian Thomson President, Canadian BioEnergy 
Ian oversees the Company's biodiesel fuel operations business and works closely with the Alberta agricultural community in advance of the company's proposed production facility in Sturgeon County. Ian is a Company founder and, from September 2002, led the business through its startup market development phase to the incorporation of the Company. Ian is a pioneer and leader in the Canadian biodiesel industry, working, in 2004, to exempt biodiesel blends in BC from road fuel taxes and assisting with the establishment of the BC BioFleet program. Ian has 15 years of strategic consulting experience to organizations such as Cargill, Chevron, Duke Energy, PetroCanada, and United Technologies. Ian is a former Chartered Accountant and is the current President of the Alberta Biodiesel Association. |
 Suite 900 - 1188 West Georgia St.
Vancouver, BC V6E 4A2 |